VentriPoint Diagnostics (TSE:VPT) has released an update.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Ventripoint Diagnostics and ASCEND Cardiovascular have signed a term sheet for a non-exclusive license to integrate Ventripoint’s VMS+ technology into ASCEND’s Gen3Echo platform, aiming to enhance cardiovascular diagnostics. This collaboration promises to improve diagnostic accuracy and streamline workflows for echocardiographers by combining cutting-edge AI and machine learning technologies.
For further insights into TSE:VPT stock, check out TipRanks’ Stock Analysis page.